These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10925318)

  • 1. Status of activation of circulating vaccine-elicited CD8+ T cells.
    Nielsen MB; Monsurro V; Migueles SA; Wang E; Perez-Diez A; Lee KH; Kammula U; Rosenberg SA; Marincola FM
    J Immunol; 2000 Aug; 165(4):2287-96. PubMed ID: 10925318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanoma vaccines: the paradox of T cell activation without clinical response.
    Nielsen MB; Marincola FM
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S62-6. PubMed ID: 10950150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression.
    Lee KH; Wang E; Nielsen MB; Wunderlich J; Migueles S; Connors M; Steinberg SM; Rosenberg SA; Marincola FM
    J Immunol; 1999 Dec; 163(11):6292-300. PubMed ID: 10570323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.
    Rivoltini L; Castelli C; Carrabba M; Mazzaferro V; Pilla L; Huber V; Coppa J; Gallino G; Scheibenbogen C; Squarcina P; Cova A; Camerini R; Lewis JJ; Srivastava PK; Parmiani G
    J Immunol; 2003 Oct; 171(7):3467-74. PubMed ID: 14500642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity.
    Valmori D; Dutoit V; Schnuriger V; Quiquerez AL; Pittet MJ; Guillaume P; Rubio-Godoy V; Walker PR; Rimoldi D; Liénard D; Cerottini JC; Romero P; Dietrich PY
    J Immunol; 2002 Apr; 168(8):4231-40. PubMed ID: 11937585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional heterogeneity of vaccine-induced CD8(+) T cells.
    Monsurrò V; Nagorsen D; Wang E; Provenzano M; Dudley ME; Rosenberg SA; Marincola FM
    J Immunol; 2002 Jun; 168(11):5933-42. PubMed ID: 12023400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
    Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
    Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of CD8(-) HLA class I/epitope tetrameric complexes binding T cells.
    Nagorsen D; Monsurrò V; Wang E; Marincola FM
    J Immunother; 2002; 25(5):379-84. PubMed ID: 12218775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of TCR use in response to repeated epitope-specific immunization.
    Monsurrò V; Nielsen MB; Perez-Diez A; Dudley ME; Wang E; Rosenberg SA; Marincola FM
    J Immunol; 2001 May; 166(9):5817-25. PubMed ID: 11313426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.
    Appay V; Jandus C; Voelter V; Reynard S; Coupland SE; Rimoldi D; Lienard D; Guillaume P; Krieg AM; Cerottini JC; Romero P; Leyvraz S; Rufer N; Speiser DE
    J Immunol; 2006 Aug; 177(3):1670-8. PubMed ID: 16849476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination.
    Speiser DE; Baumgaertner P; Barbey C; Rubio-Godoy V; Moulin A; Corthesy P; Devevre E; Dietrich PY; Rimoldi D; Liénard D; Cerottini JC; Romero P; Rufer N
    J Immunol; 2006 Jul; 177(2):1338-48. PubMed ID: 16818795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.
    Panelli MC; Riker A; Kammula U; Wang E; Lee KH; Rosenberg SA; Marincola FM
    J Immunol; 2000 Jan; 164(1):495-504. PubMed ID: 10605047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response.
    Li Y; Bleakley M; Yee C
    J Immunol; 2005 Aug; 175(4):2261-9. PubMed ID: 16081794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.
    Zhang Y; Sun Z; Nicolay H; Meyer RG; Renkvist N; Stroobant V; Corthals J; Carrasco J; Eggermont AM; Marchand M; Thielemans K; Wölfel T; Boon T; van der Bruggen P
    J Immunol; 2005 Feb; 174(4):2404-11. PubMed ID: 15699177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.
    Xu S; Koski GK; Faries M; Bedrosian I; Mick R; Maeurer M; Cheever MA; Cohen PA; Czerniecki BJ
    J Immunol; 2003 Sep; 171(5):2251-61. PubMed ID: 12928369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases.
    Pittet MJ; Zippelius A; Speiser DE; Assenmacher M; Guillaume P; Valmori D; Liénard D; Lejeune F; Cerottini JC; Romero P
    J Immunol; 2001 Jun; 166(12):7634-40. PubMed ID: 11390521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
    Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI
    Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.